This HTML5 document contains 68 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/national-drug-code-directory/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n5http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/mixture/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/chebi/
n27http://bio2rdf.org/drugbank:
n26http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n15http://www.drugs.com/mtm/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/kegg-compound/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/bindingdb/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00733/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n28http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00733
rdf:type
n3:Drug
n3:description
Pralidoxime is an antidote to organophosphate pesticides and chemicals. Organophosphates bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme. If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase.
n3:dosage
n5:271B513F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
74-77 minutes
n3:indication
For the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and in the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis.
n3:manufacturer
n4:271B513D-363D-11E5-9242-09173F13E4C5 n4:271B513B-363D-11E5-9242-09173F13E4C5 n4:271B513C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00733 n27:DB00733
dcterms:title
Pralidoxime
adms:identifier
n13:Pralidoxime n21:8354 n22:DB00733 n23:50241085 n24:60977-141-01 n25:C07400 n26:PA164744926
n3:mechanismOfAction
Pralidoxime is an antidote to organophosphate pesticides and chemicals. Organophosphates bind to the esteratic site of acetylcholinesterase, which results initially in reversible inactivation of the enzyme. Acetylcholinesterase inhibition causes acetylcholine to accumulate in synapses, producing continuous stimulation of cholinergic fibers throughout the nervous systems. If given within 24 hours after organophosphate exposure, pralidoxime reactivates the acetylcholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase.
n3:packager
n4:271B5139-363D-11E5-9242-09173F13E4C5 n4:271B513A-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The drug is rapidly excreted in the urine partly unchanged, and partly as a metabolite produced by the liver.
n3:synonym
Pralidoxime Pralidoximum 2-PAM Pralidoxim Pralidoxima
n19:hasAHFSCode
n20:92-00-00
n3:mixture
n8:271B5138-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
No binding to plasma proteins
n3:salt
n17:hasConcept
n18:M0092337
foaf:page
n15:pralidoxime-injection.html n16:pralidoxime.htm
n3:IUPAC-Name
n6:271B5144-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B514A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5149-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B5146-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5147-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5148-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B5142-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5143-363D-11E5-9242-09173F13E4C5 n6:271B515B-363D-11E5-9242-09173F13E4C5 n6:271B5140-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5141-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n28:V03AB04
n3:H-Bond-Acceptor-Count
n6:271B5150-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5151-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B514B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B514C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B514E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B514D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B514F-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
6735-59-7
n3:category
n3:containedIn
n7:271B513E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5156-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5158-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5159-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B515A-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5155-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5154-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B5157-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5145-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B5152-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5153-363D-11E5-9242-09173F13E4C5